These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

631 related articles for article (PubMed ID: 15717629)

  • 41. Apoptosis-associated markers and clinical outcome in human oral squamous cell carcinomas.
    Kato K; Kawashiri S; Yoshizawa K; Kitahara H; Yamamoto E
    J Oral Pathol Med; 2008 Jul; 37(6):364-71. PubMed ID: 18410312
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The significance of VEGF-C/VEGFR-2 interaction in the neovascularization and prognosis of nephroblastoma (Wilms' tumour).
    Nowicki M; Ostalska-Nowicka D; Kaczmarek M; Miskowiak B; Witt M
    Histopathology; 2007 Feb; 50(3):358-64. PubMed ID: 17257131
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Quality assessment for Wilms' tumor: a report from the National Wilms' Tumor Study-5.
    Ehrlich PF; Ritchey ML; Hamilton TE; Haase GM; Ou S; Breslow N; Grundy P; Green D; Norkool P; Becker J; Shamberger RC
    J Pediatr Surg; 2005 Jan; 40(1):208-12; discussion 212-3. PubMed ID: 15868587
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Risk factors for perioperative complications in renal surgery for Wilms' tumor].
    Seseke F; Rebmann S; Zöller G; Lakomek M; Ringert RH
    Aktuelle Urol; 2007 Jan; 38(1):46-51. PubMed ID: 17290329
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Bcl-2, bax and p53 expression in rectal adenocarcinoma. Correlation with classic pathologic prognostic factors and patients' outcome.
    Tsamandas AC; Kardamakis D; Petsas T; Zolota V; Vassiliou V; Matatsoris T; Kalofonos H; Vagianos CE; Scopa CD
    In Vivo; 2007; 21(1):113-8. PubMed ID: 17354623
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Minichromosome maintenance 2 (MCM2) is a new prognostic proliferative marker in Wilms tumour.
    Taran K; Sitkiewicz A; Andrzejewska E; Kobos J
    Pol J Pathol; 2011; 62(2):84-8. PubMed ID: 21866463
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Quantitative evaluation of the apoptosis regulating genes Survivin, Bcl-2 and Bax in inflammatory and malignant pleural lesions.
    Falleni M; Pellegrini C; Marchetti A; Roncalli M; Nosotti M; Palleschi A; Santambrogio L; Coggi G; Bosari S
    Lung Cancer; 2005 May; 48(2):211-6. PubMed ID: 15829320
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Bcl-2, bcl-x, and bax expression in dysembryoplastic neuroepithelial tumors.
    Prayson RA
    Clin Neuropathol; 2000; 19(2):57-62. PubMed ID: 10749285
    [TBL] [Abstract][Full Text] [Related]  

  • 49. WT1 induces apoptosis through transcriptional regulation of the proapoptotic Bcl-2 family member Bak.
    Morrison DJ; English MA; Licht JD
    Cancer Res; 2005 Sep; 65(18):8174-82. PubMed ID: 16166292
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The potential role of Bcl-2 expression, apoptosis and cell proliferation (Ki-67 expression) in cases of gastric carcinoma and correlation with classic prognostic factors and patient outcome.
    Tsamandas AC; Kardamakis D; Tsiamalos P; Liava A; Tzelepi V; Vassiliou V; Petsas T; Vagenas K; Zolota V; Scopa CD
    Anticancer Res; 2009 Feb; 29(2):703-9. PubMed ID: 19331225
    [TBL] [Abstract][Full Text] [Related]  

  • 51. High expression levels of x-linked inhibitor of apoptosis protein and survivin correlate with poor overall survival in childhood de novo acute myeloid leukemia.
    Tamm I; Richter S; Oltersdorf D; Creutzig U; Harbott J; Scholz F; Karawajew L; Ludwig WD; Wuchter C
    Clin Cancer Res; 2004 Jun; 10(11):3737-44. PubMed ID: 15173080
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Progression of localised Wilms' tumour during preoperative chemotherapy is an independent prognostic factor: a report from the SIOP 93-01 nephroblastoma trial and study.
    Ora I; van Tinteren H; Bergeron C; de Kraker J;
    Eur J Cancer; 2007 Jan; 43(1):131-6. PubMed ID: 17084075
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Multidrug resistance-related phenotype and apoptosis-related protein expression in ovarian serous carcinomas.
    Yakirevich E; Sabo E; Naroditsky I; Sova Y; Lavie O; Resnick MB
    Gynecol Oncol; 2006 Jan; 100(1):152-9. PubMed ID: 16198399
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Blastemal cells of nephroblastomatosis complex share an onco-developmental antigen with embryonic kidney and Wilms' tumor. An immunohistochemical study on polysialic acid distribution.
    Roth J; Blaha I; Bitter-Suermann D; Heitz PU
    Am J Pathol; 1988 Dec; 133(3):596-608. PubMed ID: 2849302
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Aspiration cytology of Wilms' tumor.
    Dey P; Radhika S; Rajwanshi A; Rao KL; Khajuria A; Nijhawan R; Banarjee CK
    Acta Cytol; 1993; 37(4):477-82. PubMed ID: 8392251
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The effect of chemotherapy on Ki-67, Bcl-2 and Bak expression in primary tumors and lymph node metastases of breast cancer.
    Koda M; Sulkowska M; Kanczuga-Koda L; Tomaszewski J; Kucharczuk W; Lesniewicz T; Cymek S; Sulkowski S
    Oncol Rep; 2007 Jul; 18(1):113-9. PubMed ID: 17549355
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The nephroblastomatosis complex and its relationship to Wilms' tumor: a clinicopathologic treatise.
    Bove KE; McAdams AJ
    Perspect Pediatr Pathol; 1976; 3():185-223. PubMed ID: 184429
    [TBL] [Abstract][Full Text] [Related]  

  • 58. p53 immunopositivity in histologically favorable Wilms tumor is not related to stage at presentation or to biological aggression.
    D'Angelo MF; Kausik SJ; Sebo TJ; Rathbun SR; Kramer SA; Husmann DA
    J Urol; 2003 May; 169(5):1815-7. PubMed ID: 12686851
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Histological analysis of aggressiveness and responsiveness in Wilms' tumor.
    Beckwith JB; Zuppan CE; Browning NG; Moksness J; Breslow NE
    Med Pediatr Oncol; 1996 Nov; 27(5):422-8. PubMed ID: 8827069
    [TBL] [Abstract][Full Text] [Related]  

  • 60. High telomerase RNA expression level is an adverse prognostic factor for favorable-histology Wilms' tumor.
    Dome JS; Bockhold CA; Li SM; Baker SD; Green DM; Perlman EJ; Hill DA; Breslow NE
    J Clin Oncol; 2005 Dec; 23(36):9138-45. PubMed ID: 16172460
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.